ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Vasculitis"

  • Abstract Number: 2504 • ACR Convergence 2024

    Polyarteritis Nodosa Associated with VEXAS Syndrome and Chronic Myelomonocytic Leukemia Compared with Primary Forms: A Case-Control Study

    Paul Cioni1, Yann Nguyen2, Julien ROHMER3, Henry Dupuy4, Xavier Puéchal5, Estibaliz Lazaro6, Grégory Pugnet7, Cécile-Audrey Durel8, Edoardo Conticini9, François Lifermann10, Philip Bielefeld11, pierre duffau4, Hartmut Mahrhofer12, Alexis Régent5, Loïc Guillevin13, ludovic trefond14, Christian AGARD15, Alice Bérezné16, Valentin Lacombe17, Perrine SMETS18, Sophie Georgin-lavialle19, Arsene Mekinian20 and Benjamin Terrier21, and the French Vasculitis Study Group and the French Vexas Group, 1Cochin University Hospital, Paris, France, 2Université Paris Saclay, Clichy, Ile-de-France, France, 3APHP, Suresnes, France, 4Bordeaux University Hospital, Bordeaux, France, 5National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, 6Bordeaux University Hospital, Pessac, France, 7Toulouse Rangueil University Hospital, Toulouse, France, 8Edouard Herriot University Hospital, Lyon, France, 9University of Siena, Siena, Siena, Italy, 10Dax Hospital, Dax, France, Dax, France, 11Dijon University Hospital, Dijon, France, 12Kirchheim Clinic, Kirchheim unter Teck, Germany, 13National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, 14Clermont Ferrand University Hospital, Clermont Ferrand, France, 15Nantes University Hospital, Nantes, France, 16Annecy Genevois Hospital, Annecy, France, 17Angers University Hospital, Angers, France, 18Clermont Ferrand University Hospital - National reference center for autoimmune disease, Internal Medicine, Clermont-Ferrand, France, 19Sorbonne Université, Department of internal medicine, Tenon Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, 20Saint Antoine University Hospital, Paris, France, 21Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France

    Background/Purpose: Polyarteritis nodosa (PAN) is a systemic necrotizing vasculitis affecting medium-sized vessels. It is a life-threatening disease without appropriate treatment. In 2024, approximately one quarter…
  • Abstract Number: 2628 • ACR Convergence 2024

    Clinical Features, Treatments, and Outcomes of a Large International Cohort of Childhood-onset Takayasu Arteritis: A PedVas Study

    James Bistolarides1, Vidya Sivaraman2, Else Bosman3, Linda Wagner-Weiner4, Kimberly Morishita5, James Nocton1, Melodee Liegl1, Amy Pan1 and David Cabral6, and PedVas Investigators Network, 1Medical College of Wisconsin, Milwaukee, WI, 2Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, 3UBC, Vancouver, BC, Canada, 4University of Chicago, Chicago, IL, 5University of British Columbia - Vancouver, Vancouver, BC, Canada, 6BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: Takayasu arteritis (TAK) is a rare systemic vasculitis. It occurs most commonly in patients aged < 40 years (y), and 32% of patients present…
  • Abstract Number: 0737 • ACR Convergence 2024

    Rurality and Delayed Diagnosis of Giant Cell Arteritis – a Single Center Experience

    Ruoning (Lemon) Ni1, Bharat Kumar2 and Aleksander Lenert3, 1Cleveland Clinic, Cleveland, OH, 2University of Iowa Hospitals and Clinics, Iowa City, IA, 3University of Iowa, Iowa City, IA

    Background/Purpose: Giant Cell Arteritis (GCA) poses diagnostic challenges, especially in rural areas, where limited access to healthcare can delay diagnosis and worsen outcomes, a concern…
  • Abstract Number: 0766 • ACR Convergence 2024

    Neutrophil Transcriptomics in VEXAS Syndrome

    Chloe Palmer1, Gustaf Wigerblad1, Tom Hill2, Bhavisha Patel3, Emma Groarke4, Neal Young4, Stefania Dell'Orso5 and Peter Grayson6, 1National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 2National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, 3National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Beltsville, MD, 4National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, 5National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD, 6National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD

    Background/Purpose: Vacuoles, E1 ubiquitin-activating enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is caused by somatic mutations of the ubiquitin-like modifier activating enzyme 1 (UBA1) gene and…
  • Abstract Number: 1597 • ACR Convergence 2024

    Baseline Glucocorticoid-Related Toxicity in Newly-Diagnosed and Relapsing ANCA-Associated Vasculitis

    Naomi Patel1, Sarah Bray2, Darcy Trimpe3, David Jayne4, Peter Merkel5 and John Stone6, 1Massachusetts General Hospital, Boston, MA, 2Amgen Ltd, Cambridge, United Kingdom, 3Amgen Inc., Thousand Oaks, CA, 4University of Cambridge, Cambridge, United Kingdom, 5University of Pennsylvania, Philadelphia, PA, 6Massachusetts General Hospital , Harvard Medical School, Concord, MA

    Background/Purpose: The ADVOCATE trial evaluated avacopan (a C5a receptor antagonist) as a replacement for a standard prednisone taper in the treatment of granulomatosis with polyangiitis…
  • Abstract Number: 1630 • ACR Convergence 2024

    Disease Manifestations, Diagnostic Findings, and Mortality of 120 Consecutive Patients Suspected of Giant Cell Arteritis – Results from a Hospital GCA Fast-Track Clinic

    Uffe Moller Dohn1, Tanja Fromberg Gorlen2, Rikke Westergaard1, Viktoria Fana1, Torsten Møller1 and Lene Terslev3, 1Rigshospitalet-Glostrup, Glostrup, Denmark, 2Rigshospitalet-Glostrup & COPECARE, Glostrup, Hovedstaden, Denmark, 3Rigshospitalet-Glostrup & COPECARE, Glostrup, Denmark

    Background/Purpose: Giant cell arteritis (GCA) is a large-vessel vasculitis affecting the large vessels from aorta, its proximal branches, and the extra-cranial arteries. To avoid ischemic…
  • Abstract Number: 2180 • ACR Convergence 2024

    The Association Between Age at Diagnosis and Patient-Reported Outcomes in Patients with Vasculitis

    Jessica Bloom1, Kaci Pickett-Nairne2, Lori Silveira2, David Cuthbertson3, Carol McAlear4, Peter Merkel4 and Karen James5, and the Vasculitis Clinical Research Consortium, 1University of Colorado, Denver, CO, 2University of Colorado, Aurora, CO, 3University of South Florida, Tampa, FL, 4University of Pennsylvania, Philadelphia, PA, 5University of Utah, Salt Lake City, UT

    Background/Purpose: Vasculitis is a chronic autoimmune condition that significantly impacts patients’ quality of life. It is unknown whether the degree of this impact varies based…
  • Abstract Number: 2505 • ACR Convergence 2024

    C5 Signaling Pathway Genes as Key Drivers of the Pathogenesis of IgA Vasculitis?

    Joao Carlos Batista-Liz1, Vanesa Calvo-Rio2, María Sebastián Mora-Gil3, Ligia Gabrie-Rodriguez4, Rafael Gálvez Sánchez4, Belén Sevilla-Pérez5, José Luis Callejas6, María Teresa Leonardo7, Ana Peñalba7, Javier Narvaez-García8, Luis Martín-Penagos9, Luis Caminal-Montero10, PAZ COLLADO11, Patricia Quiroga Colina12, Esther Vicente-rabaneda13, Esteban Rubio14, Manuel León Luque15, Juan María Blanco-Madrigal16, Eva Galindez-Agirregoikoa17, Santos Castañeda13, Ricardo Blanco-Alonso18, Veronica Pulito-Cueto1 and Raquel Lopez-mejias1, 1IDIVAL, Santander, Spain, 2Valdecilla Hospital, Santander, Cantabria, Spain, 3Immunopathology Group, IDIVAL, Santander, Spain, 4Immunopathology Group, IDIVAL. Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 5Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, 6Systemic Autoimmune Diseases Unit, Hospital Clinico San Cecilio, Instituto de Investigación Biosanitaria de Granada ibs.GRANADA, Granada, Spain, 7Division of Pediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 8Hospital Universitario de Bellvitge, Barcelona, Spain, 9Immunopathology Group, IDIVAL. Division of Nephrology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 10Internal Medicine Department, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain, 11Hospital Universitario Severo Ochoa, MADRID, Spain, 12Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, 13Hospital Universitario de La Princesa, Madrid, Spain, 14Division of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, Sevilla, Spain, 15Division of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain., Sevilla, Spain, 16Division of Rheumatology, Hospital Universitario de Basurto, Bilbao, Spain., Bilbao, Spain, 17BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, 18Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: Immunoglobulin A Vasculitis (IgAV) is an inflammatory disease caused by the accumulation of immune complexes of IgA in the walls of small blood vessels…
  • Abstract Number: 2647 • ACR Convergence 2024

    Clinical Characteristics , Treatment Outcomes and Predictors of Mortality in a DADA2 Cohort of 101 Patients

    Aman Sharma1, Niladri Bhowmick2, shankar naidu3, Varun Dhir4, Prateek Bhatia3, Vishal Sharma3, sagar Bhattad5, Chengappa Kavadichanda6, Vikas Gupta7, Durga P Misra8, Sourabh Malviya9, DUDAM RAJKIRAN10, Banwari Sharma11, John Mathew12, Sathish Kumar13, Rajesh Bhojwani14, Aadhaar Dhooria15, Avinash Jain16, Pankaj Gupta17, Vikas Agarwal8, Rudrarpan Chatterjee18, Kusum Sharma19, Manphool Singhal19, Harjeet Singh19, Alpana Parmar20, Padmanbha Shenoy21, Ritambhra Nada19, Ranjana Minz19, Archana Khan22, Sodality Sutnga22, Minu Singh19, Kaushik Bhojani23, MAHABALESHWAR MAMADAPUR24, Manesh Manoj25, Puja Srivastava26, Adarsh MB27, Kavita Krishna28, Ramesh Jois29, Vir Singh Negi30, Amita Aggarwal31, sanjay jain19, Raju Khubchandani32, Chip Chambers33 and Pui Lee34, 1PGIMER, Chandigarh, India, Chandigarh, Chandigarh, India, 2Post Graduate Institute of Medical Education and Research , Chandigarh, Chandigarh, Chandigarh, India, 3PGIMER, Chandigarh, India, Chandigarh, India, 4PGIMER, CHD, INDIA, CHANDIGARH, India, 52Aster CMI Hospital, Bengaluru, India, Bengaluru, 6Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India, 7Fortis Hospital, Ludhiana, India, Ludhiana, 8Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, 9Medanta superspeciality hospital, Indore, India, 10Hyderabad Rheumatology Centre, Hyderabad, India, HYDERABAD, Andhra Pradesh, India, 11Niramaya Healthcare, Jaipur, India, Jaipur, India, 12Christian Medical college , Vellore , India, Vellore, India, 13CMC, Vellore, Vellore, India, 14Santokba Durlabhji Memorial Hospital, Jaipur, India, Jaipur, India, 15Mahatma Gandhi Medical College and Hospital Jaipur, Jaipur, Rajasthan, India, 16Sawai Man Singh Hospital, Lucknow, Rajasthan, India, 17PGIMER, Chandigarh, India, Chandigarh, 18Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow., Lucknow, Uttar Pradesh, India, 19PGIMER, Chandigarh, Chandigarh, India, 20Rheumatology Clinic, Surat, India, Surat, India, 21Center for arthritis and rheumatims excellence ( CARE, Cochin, Kerala, India, 22SRCC Children’s Hospital, Mumbai, India, Mumbai, India, 23Fortis Hospital, Mumbai, Mumbai, India, 24JSS MEDICAL COLLEGE AND HOSPITAL,JSSAHER, Mysore, Karnataka, India, 25AKG Memorial Cooperative Hospital Kannur, Nileshwar, Kerala, India, 26STAR Rheumatology Clinics, Ahmedabad, India, Ahmedabad, India, 27Government Medical College, Kozhikode, India, Kozhikode, India, 28Bharati Vidyapeeth Medical College, Pune, Pune, India, 29Manipal Hospital ,Rheumatology, Millers Road, Bengaluru, India, Bengaluru, India, 30AIIMS, Bilaspur, Puducherry, Puducherry, India, 31Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India, 32SRCC Childrens Hospital, Mumbai, India, 33Vanderbilt University Medical Center & DADA2 Foundation, Franklin, TN, 34Boston Children's Hospital, Newton, MA

    Background/Purpose: Deficiency of adenosine deaminase 2 (DADA2) is a rare and potentially life threatening monogenic disorder characterized by systemic vasculitis, bone marrow failure, and immunodeficiency.…
  • Abstract Number: 0742 • ACR Convergence 2024

    Use of FDG-PET to Monitor Disease Activity in Patients with Giant Cell Arteritis on Tocilizumab

    Kaitlin Quinn1, mark ahlman2 and Peter Grayson3, 1National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 2Radiology and Imaging, Medical College of Georgia, augusta, GA, 3National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD

    Background/Purpose: The optimal way to monitor disease activity in patients with GCA on tocilizumab remains uncertain.  Acute phase reactants are not a reliable indicator of…
  • Abstract Number: 0767 • ACR Convergence 2024

    Comparing Large Vessel Uptake of 68Ga-HA-DOTATATE to 18F-FDG Using PET/CT Imaging in Patients with Active Giant Cell Arteritis

    Alison Clifford1, Jonathan Abele1, Ryan Hung1, Paolo Raggi1, Frank Wuest1, Jan Andersson1, Elaine Yacyshyn2, Eric Lenza1, Glen Jickling1 and Jan Willem Cohen Tervaert1, 1University of Alberta, Edmonton, Canada, 2University of Alberta, Edmonton, AB, Canada

    Background/Purpose: 18F-fluoro-deoxyglucose (FDG) is the current standard among radiotracers for PET/CT imaging of large vessel vasculitis (LVV) in giant cell arteritis (GCA), but its performance…
  • Abstract Number: 1598 • ACR Convergence 2024

    Projecting the Impact of Standard, Reduced-Dose, and Minimal-Dose Glucocorticoid Regimens in the Treatment of ANCA-Associated Vasculitis Using Simulation Modeling

    Naomi Patel1, Aaron Wu1, Shruthi Srivatsan1, Eli Miloslavsky2, Peter Merkel3, John Stone4, Hyon K. Choi5, Emily Hyle1 and Zachary Wallace2, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Newton, MA, 3University of Pennsylvania, Philadelphia, PA, 4Massachusetts General Hospital , Harvard Medical School, Concord, MA, 5Massachusetts General Hospital, Lexington, MA

    Background/Purpose: Glucocorticoids (GCs) remain a cornerstone of treatment of ANCA-associated vasculitis (AAV) but predispose people to infectious, metabolic, and other toxicities. We projected the long-term…
  • Abstract Number: 1632 • ACR Convergence 2024

    Multi-vessel Intimal Medial Thickness in Takayasu Arteritis: A Potential Marker for Disease Modification?

    Augustine Jose1, Molly Thabah2, Chengappa Kavadichanda3, Jagan K L2, Christina Mariaselvam4 and Vir Singh Negi5, 1Jawaharlal Institute of Postgraduate Medical Education and Research, Gorimedu, Puducherry, India, 2Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Puducherry, India, 3Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India, 4JIPMER, Puducherry, Puducherry, India, 5AIIMS, Bilaspur, Puducherry, Puducherry, India

    Background/Purpose: Ultrasonography can measure vascular intimal-medial thickness (IMT) and delineate the degrees of stenosis in Takayasu arteritis (TAK). Further, higher IMT has been reported in…
  • Abstract Number: 2191 • ACR Convergence 2024

    Optimizing Inpatient Kawasaki Disease Care

    Audrea Chen1, Beth Gamulka2, Macarena Palomer3 and Rae Yeung4, 1The Hospital for Sick Children, Burnaby, BC, Canada, 2The Hospital for Sick Children, Toronto, 3The Hospital for Sick Children, Toronto, Canada, 4The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Kawasaki Disease (KD), an acute pediatric vasculitis, requires inpatient management to prevent coronary artery disease. The Hospital for Sick Children (SickKids) sees about 100…
  • Abstract Number: 2506 • ACR Convergence 2024

    THP1-derived Macrophage Polarization in Takayasu Arteritis – Impact of Disease Status and Therapy

    João Paulo dos Santos1, Cristina Orikaza1, Mariana Aguiar2, Gerson Keppeke3 and Alexandre de Souza4, 1Universidade Federal de Sao Paulo, São Paulo, SP, Brazil, 2Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil, 3Universidad Catolica del Norte, São Paulo, Coquimbo, Brazil, 4UNIFESP-EPM, São Paulo, SP, Brazil

    Background/Purpose: Macrophages play an important role in the pathophysiology of Takayasu arteritis (TAK) as granulomatous inflammation is typically found in affected arteries. The expression of…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 35
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology